Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared to the Russell 2000 Index’s +0.9% return and the HFRX Equity Hedge Index’s -1.5% return. Long book performance was negative, while the short book contributed positively. Geopolitics significantly influenced the first quarter, contributing to increased inflation pressures and elevated energy prices. Additionally, you can review the Portfolio’s top 5 holdings to see its best picks for 2026.
In its first-quarter 2026 investor letter, Prosper Stars & Stripes highlighted BioLife Solutions, Inc. (NASDAQ:BLFS). BioLife Solutions, Inc. (NASDAQ:BLFS) is a biotechnology company that develops and manufactures bioproduction products and services for the cell and gene therapy (CGT) industry. On June 16, 2026, BioLife Solutions, Inc. (NASDAQ:BLFS) closed at $25.58 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was 3.40%, and its shares gained 18.87% over the past 52 weeks. BioLife Solutions, Inc. (NASDAQ:BLFS) has a market capitalization of $1.29 billion.
Prosper Stars & Stripes stated the following regarding BioLife Solutions, Inc. (NASDAQ:BLFS) in its Q1 2026 investor letter:
“We actively monitor our Focus List to revisit compelling ideas when risk/reward becomes favorable. This discipline drove both our decision to reinvest in Vishay Precision and to add BioLife Solutions, Inc. (NASDAQ:BLFS) back into the portfolio. BioLife has had an eventful history as a public company. The company’s former CEO pursued an acquisition strategy that we believe diluted rather than enhanced the company’s core strengths. Current CEO Roderick de Greef has largely reversed that course, divesting most of those businesses and refocusing the company on its highest-quality products. The result is a cleaner, more focused business, better positioned to capitalize on the underlying growth in its end markets. The cornerstone of the business has always been biopreservation media, a product with a high growth rate and exceptional margins. This is an excellent example of a ‘picks & shovel’ business in healthcare. The media is used by customers in the manufacturing of cell-based therapies, an end-market expected to grow over 20% annually over the next five years. The recent underperformance of healthcare and life science tools stocks brought BioLife’s valuation to a level where we again see a compelling long opportunity. With 20%-plus top-line growth 13 and meaningful margin expansion driving rapid EBITDA growth, we believe the stock offers a compelling risk/reward from current levels.”
BioLife Solutions, Inc. (NASDAQ:BLFS) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 13 hedge fund portfolios held BioLife Solutions, Inc. (NASDAQ:BLFS) at the end of the first quarter, compared to 15 in the previous quarter. In Q1 2026, BioLife Solutions, Inc. (NASDAQ:BLFS) reported total revenue of $27.5 million, increasing 25% year-over-year. While we acknowledge the risk and potential of BioLife Solutions, Inc. (NASDAQ:BLFS) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BIOLIFE SOLUTIONS, INC. (NASDAQ:BLFS) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
